Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78
Tip Ranks·- Needham analyst Serge Belanger reaffirmed a buy rating on Xenon Therapeutics with a price target of 78 USD. - The decision is supported by the upcoming AZK project progress, including an NDA submission for focal-onset seizures planned for Q3 2026 and strong clinical milestones. - The company possesses robust financial stability with approximately 1.2 billion USD in cash reserves to fund development and commercialization.